South Africa Pharmaceuticals & Healthcare Q1 2019
Despite the elevated risk profile for multinational drugmakers in South Africa, the country will remain the largest andmost developed in Sub-Saharan Africa, retaining its attractive status for innovative medicine launches. Nevertheless, South Africa’sconsiderable market size leaves it exposed to a number of external influences, both industry and macroeconomic related. Keydevelopments to watch over the near term include the impact of the reformed intellectual property policy on local and foreigndrugmakers, reforms to the National Health insurance Scheme and the ability of ‘South African Health Products RegulatoryAuthority’ to clear its pipeline of backlogged medicines.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook